Ignite Creation Date:
2024-10-25 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06632470
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-07
Brief Title:
Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment Dementia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment Dementia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial if to learn if Human Umbilical Cord Mesenchymal Stem Cell HUCMSC derived secretome injection is safe and effective in patient with moderate dementia The main questions it aims to answer are
1 Is HUCMSC derived secretome safe to be use as a therapy in patients with moderate dementia
2 How does HUCMSC derived secretome affect pro inflammatory and anti inflammatory cytokine IL-6 and TNF alfa in patient with moderate dementia
3 What is the relationship between HUCMSC derived secretome therapy with mini mental state examination Researchers will compare the intervention group patients who are injected with HUCMSC derived secretome and control group patients who are only monitored
Participants will
Be injected with HUCMSC derived secretome or Vitamin B12 every two weeks for 4 months
Follow up visit to review treatment progress on 3rd months 2 weeks post treatment 7th months 3 months post treatment and participants will do several blood test and mental examination
1 Is HUCMSC derived secretome safe to be use as a therapy in patients with moderate dementia
2 How does HUCMSC derived secretome affect pro inflammatory and anti inflammatory cytokine IL-6 and TNF alfa in patient with moderate dementia
3 What is the relationship between HUCMSC derived secretome therapy with mini mental state examination Researchers will compare the intervention group patients who are injected with HUCMSC derived secretome and control group patients who are only monitored
Participants will
Be injected with HUCMSC derived secretome or Vitamin B12 every two weeks for 4 months
Follow up visit to review treatment progress on 3rd months 2 weeks post treatment 7th months 3 months post treatment and participants will do several blood test and mental examination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None